Analog Curcumin, Pentagamavunon-0 (PGV-0), Induces Senescence and Increases Cytotoxic Effect of Doxorubicin on HCC 1954 Cells

Sonia Meta Angraini, Nadzifa Nugraheni, Edy Meiyanto, Adam Hermawan

Abstract


Senescence defined as an irreversible cell cycle arrest. Senescence can inhibit cancer growth and suppress the progression of cancer. Some anticancer compounds are known to have the potential to induce senescence. Senescence defence against tumor development by preventing proliferation of cells with DNA damage. The study aimed to determine the cytotoxic effects and senescence induction of Pentagamavunon-0 (PGV-0) on Human Epidermal Growth Factor Receptor 2-positive (HER2-positive) breast cancer cells, HCC 1954. Cytotoxic tests carried out with 3- (4.5-dimethylthiazzol-2yl) -2.5-tidiphenyltetrazolium (MTT) assay showed that PGV-0 exhibited a strong cytotoxic effect with a the half maximal inhibitory concentration (IC50) value of 39 μM. Treatment with IC50 in sub-doses combined with doxorubicin showed cytotoxic enhancement effects. The senescence assay using SA-β-Galactosidase showed that the PGV-0 in a single treatment was able to induce senescence with a percentage of cell senescent of 15%. The combination treatment of PGV-0 at the half dose of IC50 with doxorubicin 100 nM was able to induce senescence with the percentage of senescent cells of 25%. Moreover, PGV-0 also increased intracellular reactive oxygen species (ROS). The results of this study indicate that PGV-0 exhibits cytotoxic effect, increases cytotoxic effect of doxorubicin and induces senescence that may correlate to the increasing of intracellular ROS in 1954 HCC cells.


Keywords: Pentagamavunon (PGV-0), HCC 1954, Cytotoxic, Senescence


Full Text:

PDF

References


Campisi, J., 2013, Aging, cellular senescence, and cancer, Annu. Rev. Physiol., 75, 685–705. CrossRef

Campisi, J., 1997, Aging and cancer: the double-edged sword of replicative senescence, J Am Geriatr Soc., 45, 482–488. CrossRef

Dawood, S., Broglio, K., Buzdar, A.U., Hortobagyi, G.N. and Giordano, S.H., 2010, Prognosis of women with metastatic breast cancer by HER2 status and trastuzumab treatment: an institutional-based review, J. Clin. Oncol., 28, 92–98. CrossRef

Debacq-Chainiaux, F., Erusalimsky, J.D., Campisi, J. and Toussaint, O., 2009, Protocols to detect senescence-associated beta-galactosidase (SA-betagal) activity, a biomarker of senescent cells in culture and in vivo, Nat Protoc., 4, 1798–1806. CrossRef

Hermawan, A., Fitriasari, A., Junedi, S., kawati, M., Haryanti, S., Widaryanti, B., Da’i, M., and Meiyanto, E., 2011, PGV-0 and PGV-1 Increased Apoptosis Induction of Doxorubicin on MCF-7 Breast Cancer Cells, Pharmacon, 12(2), 55-59.

Huun, J., Lønning, P.E. and Knappskog, S., 2017. Effects of concomitant inactivation of p53 and pRb on response to doxorubicin treatment in breast cancer cell lines, Cell Death Discov., 3, 17026. CrossRef

Ikawati, M. and Septisetyani, E.P., 2018, Pentagamavunone-0 (PGV-0), a Curcumin Analog, Enhances Cytotoxicity of 5-Fluorouracil and Modulates Cell Cycle in WiDr Colon Cancer Cells, Indonesian Journal of Cancer Chemoprevention, 9(1), 23–31. CrossRef

Kusumastuti, R., Utomo, R.Y. Khumaira, A., Putri, H., Jenie, R.I. and Meiyanto, E., 2019, Pentagamaboronon-0 increased cytotoxicity of and inhibited metastasis induction by doxorubicin in breast cancer cells, Journal of Applied Pharmaceutical Science, 9(6), 043-051. CrossRef

Larasati, Y.A., Yoneda-Kato, N., Nakamae, I., Yokoyama, T., Meiyanto, E. and Kato, J., 2018, Curcumin targets multiple enzymes involved in the ROS metabolic pathway to suppress tumor cell growth, Scientific Reports, 8, 2039. CrossRef

McDermott, M.S.J., Conlon, N., Browne, B.C., Szabo, A., Synnott, N.C., O’Brien, N.A., Duffy, M.J., Crown, J. and O’Donovan, N., 2019, HER2-Targeted Tyrosine Kinase Inhibitors Cause Therapy-Induced-Senescence in Breast Cancer Cells, Cancers (Basel), 11(2), 197. CrossRef

Meiyanto, E., 2011, PGV-0 and PGV-1 Increased Apoptosis Induction of Doxorubicin on MCF-7 Breast Cancer Cells, Pharmacon: Jurnal Farmasi Indonesia, 12(2), 55-59. CrossRef

Meiyanto, E., Nakamae, I., Kawaichi, M., Kato, J.-Y., Lestari, B., Ikawati, M., Yoneda-Kato, N., Utomo, R., Jenie, R., Putri, H. and Larasati, Y., 2019, Anti-proliferative and Anti-metastatic Potential of Curcumin Analogue, Pentagamavunon-1 (PGV-1), Toward Highly Metastatic Breast Cancer Cells in Correlation with ROS Generation, Advanced Pharmaceutical Bulletin, 9(3), 445–452. CrossRef

Meiyanto, E., Putri, D.D.P., Susidarti, R.A., Murwanti, R., Sardjiman, null, Fitriasari, A., Husnaa, U., Purnomo, H. and Kawaichi, M., 2014, Curcumin and its analogues (PGV-0 and PGV-1) enhance sensitivity of resistant MCF-7 cells to doxorubicin through inhibition of HER2 and NF-kB activation, Asian Pac. J. Cancer Prev., 15, 179–184.

Meiyanto, E., Septisetyani, E.P., Larasati, Y.A. and Kawaichi, M., 2018, Curcumin Analog Pentagamavunon-1 (PGV-1) Sensitizes Widr Cells to 5-Fluorouracil through Inhibition of NF-κB Activation, Asian Pac J Cancer Prev., 19(1), 49–56. CrossRef

Mosmann, T., 1983, Rapid colorimetric assay for cellular growth and survival: application to proliferation and cytotoxicity assays, J. Immunol. Methods, 65, 55–63.

Qodria, L., Hairunisa, I., Utomo, R.Y., Hermawan, A. and Meiyanto, E., 2018, Anti-metastatic Activity of Curcumin Analog Pentagamaboronon-0-Sorbitol Against HER2-overexpressed MCF-7 Breast Cancer Cells, Indonesian Journal of Cancer Chemoprevention, 9(3), 118–125. CrossRef

Sa, G. and Das, T., 2008, Anti cancer effects of curcumin: cycle of life and death, Cell Div, 3, 14. CrossRef

Slamon, D.J., Godolphin, W., Jones, L.A., Holt, J.A., Wong, S.G., Keith, D.E., Levin, W.J., Stuart, S.G., Udove, J. and Ullrich, A., 1989, Studies of the HER-2/neu proto-oncogene in human breast and ovarian cancer, Science, 244(4905), 707–712. CrossRef

Sliwinska, M.A., Mosieniak, G., Wolanin, K., Babik, A., Piwocka, K., Magalska, A., Szczepanowska, J., Fronk, J. and Sikora, E., 2009, Induction of senescence with doxorubicin leads to increased genomic instability of HCT116 cells, Mech. Ageing Dev., 130(1-2), 24–32. CrossRef

Utomo, R.Y., Putri, H., Pudjono, P., Susidarti, R.A., Jenie, R.I. and Meiyanto, E., 2017, Synthesis and Cytotoxic Activity of 2,5-Bis(4-Boronic Acid)Benzylidine Cyclopentanone on HER2 Overexpressed-Cancer Cells, Indonesian Journal of Pharmacy, 28(2), 74-78.




DOI: http://dx.doi.org/10.14499/indonesianjcanchemoprev10iss3pp114-121

Copyright (c) 2019 Sonia Meta Angraini

Indexed by:

               

               

      

 

Indonesian Society for Cancer Chemoprevention